[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100252492":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":32,"centralContacts":20,"locations":39,"responsibleParty":50,"collaborators":20,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":76,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"National University of Singapore","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Ca-41 & Sr-84 (isotope tracers) & vit D","Dosages: 3.7 kBq (100 nCi) Ca-41, 5 mg of Sr-84 and 400IU of vitamin D (daily)",[12,13,14],"Other: Ca-41(isotope tracer)","Other: Sr-84 (isotope tracer)","Dietary Supplement: Vitamin D",[16,21,25],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"Ca-41(isotope tracer)","Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.",[9],null,{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":20},"Sr-84 (isotope tracer)","Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.",[9],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DIETARY_SUPPLEMENT","Vitamin D","One tablet daily (400IU per tablet)",[9],[31],"Cholecalciferol",[33,36],{"name":34,"affiliation":5,"role":35},"Thomas Walczyk","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":38,"role":35},"Lawrence Lee","National University Health System",[40],{"facility":41,"status":20,"city":42,"state":42,"zip":20,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":20},"Investigational Medicine Unit","Singapore","SG",{"type":45,"coordinates":46},"Point",[47,48],103.85007,1.28967,{"lat":48,"lon":47},{"type":35,"investigatorFullName":34,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Associate Professor","100252492","comparison-of-calcium-metabolism-in-caucasian-and-asian-postmenopausal-women-of-chinese-descent-and-the-use-of-strontium-as-a-qualitative-marker-of-calcium-metabolism-100252492",false,"NCT02565602","Comparison of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism","A Comparative Study of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism in Humans","Inclusion Criteria:\n\n1. Last menstrual bleeding was at least 5 years ago.\n2. Between the ages of 50 and 75 years old.\n3. Both parents and 4 grandparents are\u002Fwere of Chinese descent. It is not a necessity for the participant, participant's parents and grandparent's to be born and raised in Singapore to participate in this study.\n4. BMI above 16 and below 30\n\nExclusion Criteria:\n\n1. Diagnosed with osteoporosis\n2. Presence of significant liver disease, malignancy (excluding myeloma in the study group), malabsorption syndrome, hypoparathyroidism, hyperparathyroidism, sarcoidosis or hyperthyroidism (from toxic multinodular goitre or Graves disease), Paget's disease osteosarcoma, acromegaly, Cushing's syndrome, hypopituitarism, diabetes mellitus or severe chronic obstructive pulmonary disease.\n3. Current smoking and an alcohol intake exceeding one standard drink per day\n4. Undergoing treatment with any of the following drugs (within the last 12 months) i) adrenocorticoid steroids (3 months or longer at anytime or \\>10 days of treatment within the previous 12 months) ii) anticonvulsant therapy iii) pharmacological doses of thyroid hormone (causing decline of TSH below normal) iv) bisphosphonates v) calcitonin vi) synthetic parathyroid hormone vii) selective estrogen receptor modulators viii) strontium ranelate ix) estrogen therapy x ) chemotherapeutic agents xi) sodium fluoride (any history of treatment with fluoride) xii) medications known to affect calcium metabolism (diuretics, antacids, calcium channel blockers etc.).\n5. Presence of any other chronic illnesses.\n6. Any other significant medical, psychiatric and\u002For social issue as determined by the investigator that would compromise subject's safety and\u002For compliance with trial procedure.\n7. Any other clinically significant screening laboratory abnormality (as determined by the investigators).",true,"FEMALE","50 Years","75 Years",{"count":64,"type":65},10,"ACTUAL","INTERVENTIONAL",[68],"NA","This study aims to: 1) quantitatively assess parameters of bone calcium balance in healthy postmenopausal Asian women of Chinese descent; 2) assess possible ethnic differences in calcium metabolism by direct comparison of acquired data in Chinese postmenopausal women with those acquired earlier in Caucasian postmenopausal women using the same methodology; 3) assess differences in calcium and strontium metabolism in parallel to evaluate if strontium stable isotopes can be used for tracing bone calcium metabolism qualitatively",[71],"Calcium Metabolism",[73,74,75],"Calcium metabolism","Osteoporosis","Postmenopausal women","COMPLETED","2016-10-13",{"date":79,"type":80},"2016-10-17","ESTIMATED",{"date":82,"type":20},"2014-02",{"date":84,"type":65},"2016-09",{"name":5,"class":6},1]